Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter

New England Journal of Medicine

Volumn 335, Issue 15, 1996, Pages 1099-1106

  Saravolatz, Louis D ^a   Winslow, Dean L ^b   Collins, Gary ^c   Hodges, James S ^c   Pettinelli, Carla ^d   Stein, Daniel S ^e   Markowitz, Norman ^f   Reves, Randall ^g   Loveless, Mark O ^h   Crane, Lawrence ⁱ   Thompson, Melanie ^j   Abrams, Donald ^k   Deyton, Lawrence ^l  

^a St John Hospital   (United States)

^b Delaware Comm Prog Clin Res AIDS   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e ALBANY MEDICAL COLLEGE   (United States)

^f HENRY FORD HOSPITAL   (United States)

^g Denver Community Programs for Clinical Research on AIDS   (United States)

^h Research and Education Group   (United States)

ⁱ WAYNE STATE UNIVERSITY   (United States)

^j AIDS Research Consortium of Atlanta   (United States)

^k Jewish Home of San Francisco   (United States)

^l NATIONAL INSTITUTES OF HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; RISK; SURVIVAL ANALYSIS; ZALCITABINE; ZIDOVUDINE;

EID: 10144258702     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199610103351503     Document Type: Article

References (24)

1. Mitsuya H, Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc Natl Acad Sci U S A 1986;83:1911-5.
2. Yarchoan R, Perno CF, Thomas RV, et al. Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1988;1:76-81.
3. Yarchoan R, Thomas RV, Pluda JM, et al. Escalating dose phase I study of intravenous and oral 2′,3′-dideoxyinosine (didanosine) in patients with AIDS or ARC. In: Proceedings of the Fifth International Conference on AIDS, Montreal, June 4-9, 1989. Ottawa, Ont.: International Development Research Centre, 1989:212. abstract.
4. Yarchoan R, Mitsuya H, Thomas RV, et al. In vivo activity against HIV and favorable toxicity profile of 2′,3′-dideoxyinosine. Science 1989;245: 412-5.
5. Yarchoan R, Mitsuya H, Pluda JM, et al. The National Cancer Institute phase I study of 2′,3′-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles. Rev Infect Dis 1990;12:Suppl 5:S522-S533.
6. Gottlieb M, Galpin J, Thompkins J, et al. 2′,3′-Dideoxycytidine (zalcitabine) in the treatment of patients with AIDS and ARC. In: Proceedings of the Fifth International Conference on AIDS, Montreal, June 4-9, 1989. Ottawa, Ont.: International Development Research Centre, 1989:212. abstract.
7. Bozzette S, Skowron G, Arrezo J, et al. ACTG 050: alternating (ALT) and intermittent (INT) zalcitabine and AZT in the treatment of persons with advanced HIV infection and hematologic intolerance to AZT. In: Abstracts of the Sixth International Conference on AIDS, San Francisco, June 20-24, 1990. Vol. 3. San Francisco: University of California, 1990:192. abstract.
8. Cooley T, Kunches LM, Saunders CA, et al. Therapy of AIDS and ARC with 2′,3′-dideoxyinosine (didanosine) given once daily: results of long-term followup. In: Abstracts of the Sixth International Conference on AIDS, San Francisco, June 20-24, 1990. Vol. 3. San Francisco: University of California, 1990:205. abstract.
9. Johnson VA, Merrill DP, Chou TC, Hirsch MS. HIV-I inhibitory interactions between 2′,3′-dideoxyinosine (didanosine) and either zidovudine (AZT), recombinant soluble CD4 (rsCD4) or recombinant interferon-alpha-A (rIFN-a-A). In: Abstracts of the Sixth International Conference on AIDS, San Francisco, June 20-24, 1990. Vol. 2. San Francisco: University of California, 1990:106. abstract.
10. Merigan TC. Treatment of AIDS with combinations of antiretroviral agents. Am J Med 1991;90(4A):Suppl:8S-17S.
11. Meng TC, Fischl MA, Boota AM, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection: a phase I/II study. Ann Intern Med 1992;116:13-20.
12. Ragni M, Dafni R, Amato DA, et al. Combination zidovudine and dideoxyinosine in asymptomatic HIV(+) patients. In: Abstracts of the Eighth International Conference on AIDS/Third STD World Congress, Amsterdam, July 19-24, 1992. Vol. 1. Amsterdam: CONGREX, 1992:Mo15. abstract.
13. Collier AC, Coombs RW, Fischl MA, et al. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med 1993;119:786-93.
14. Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis 1988; 158:1079-83.
15. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1987;36:Suppl 1: 3S-15S.
16. Lawless JF. Statistical models and methods for lifetime data. New York: John Wiley, 1982.
17. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc 1989;84:1065-73.
18. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-74.
19. Mayers DL, Japour AJ, Arduino J-M, et al. Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. Antimicrob Agents Chemother 1994;38:307-14.
20. D'Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995;122:401-8.
21. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
22. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994;343:871-81.
23. Volberding PA, Lagakos SW, Grimes JM, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection: prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA 1994; 272:437-42.
24. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995;333: 450-1.